Trental

This is indicated in-
Peripheral arterial occlusive disease (PAOD) of arteriosclerotic or diabetic origin (e.g. with intermittent claudication and rest pain)
Trophic lesions (e.g. leg ulcers and gangrene)
Cerebral vascular diseases
Circulatory disturbances of the eye in conjunction with degenerative vascular disorders.

Dosage & Administration

In principle, dosage is based on the type and severity of the circulatory disorders and on how the individual patient tolerates the drug. Usual dosage is 400 mg pentoxifylline 2 to 3 times daily. Tablets are to be swallowed whole during or shortly after a meal with sufficient amounts of liquid (approx. ½ glass).

These adverse reactions have been reported in clinical trials or post-marketing-
Investigations: Transaminases increased (Transaminase elevation), Blood pressure decreased (Fall in blood pressure)
Cardiac disorders: Arrhythmia (Cardiac arrhythmia), Tachycardia, Angina Pectoris
Blood and lymphatic system disorders: Thrombocytopenia (Thrombopenia), Leucopenia/neutropenia
Nervous system disorders: Dizziness, headache, meningitis aseptic (Aseptic meningitis)
Gastrointestinal disorders: Gastrointestinal disorder (Gastrointestinal complaints), Epigastric discomfort (Gastric pressure), Abdominal distension (Fullness), Nausea, Vomiting, Diarrhoea, Constipation, Hypersalivation
Skin and subcutaneous tissue disorders: Pruritus, Erythema (Reddening of the skin), Urticaria, Rash
Vascular disorders: Hot fush (Flushes), Haemorrhage (Bleedings)
Immune system disorders: Anaphylactic reaction, Anaphylactoid reaction, Angioedema (Angioneurotic edema), Bronchospasm, Anaphylactic shock (shock)
Hepatobiliary disorders: Cholestasis (Intrahepatic cholestasis)
Psychiatric disorders: Agitation, Sleep disorder (Sleep disturbances)

At the first signs of an anaphylactic/anaphylactoid reaction, Oxifyl CR must be discontinued or the infusion be halted immediately, and a physician must be informed. Particularly careful monitoring is required:
in patients with severe cardiac arrhythmias
in patients with myocardial infarction
in hypotensive patients
in patients with impaired renal function (creatinine clearance below 30 ml/min)
in patients with severely impaired liver function
in patients with increased bleeding
in patients treated concomitantly with Oxifyl CR and anti-vitamin K or platelet aggregation inhibitors
in patients treated concomitantly with Oxifyl CR and antidiabetic agents
in patients treated concomitantly with Oxifyl CR and ciprofoxacin
in patients treated concomitantly with Oxifyl CR and theophylline

Pentoxifylline and its metabolites improve the flow properties of blood by decreasing its viscosity. In patients with chronic peripheral arterial disease, this increases blood flow to the affected microcirculation and enhances tissue oxygenation. The precise mode of action of pentoxifylline and the sequence of events leading to clinical improvement are still to be defined. Pentoxifylline administration has been shown to produce dose-related hemorrheologic effects, lowering blood viscosity, and improving erythrocyte flexibility. Leukocyte properties of hemorrheologic importance have been modified in animal and in vitro human studies. Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation. Tissue oxygen levels have been shown to be significantly increased by therapeutic doses of pentoxifylline in patients with peripheral arterial disease.